Par Pharmaceutical, Inc. et al v. Alkem Laboratories Ltd., No. 2:23-cv-00400 (E.D. Tex. Sept. 12, 2024)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Before the Court is Defendant Mankind Pharma Limited’s Motion to Transfer Venue under 28 U.S.C. §1404(a). ( 2:22-cv-399 Dkt. No. 28 .) After consideration, the Court concludes that Mankind has not met its burden of showing that the District of Delaware would be a clearly more convenient venue than this forum. Accordingly, the Court DENIES Mankind’s Motion to Transfer. I.